Cargando…

In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa

BACKGROUND: The prevalence of antibiotic resistance is increasing, and multidrug-resistant Pseudomonas aeruginosa has been identified as a serious threat to human health. The production of β-lactamase is a key mechanism contributing to imipenem resistance in P. aeruginosa. Relebactam is a novel β-la...

Descripción completa

Detalles Bibliográficos
Autores principales:	Young, Katherine, Painter, Ronald E., Raghoobar, Susan L., Hairston, Nichelle N., Racine, Fred, Wisniewski, Douglas, Balibar, Carl J., Villafania, Artjohn, Zhang, Rumin, Sahm, Daniel F., Blizzard, Timothy, Murgolo, Nicholas, Hammond, Milton L., Motyl, Mary R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6610938/ https://www.ncbi.nlm.nih.gov/pubmed/31272373 http://dx.doi.org/10.1186/s12866-019-1522-7

Ejemplares similares

Genomic Characterization of Imipenem- and Imipenem-Relebactam-Resistant Clinical Isolates of Pseudomonas aeruginosa
por: López-Pérez, Mario, et al.
Publicado: (2021)

In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in Latin America: SMART 2018‒2020
por: Karlowsky, James A., et al.
Publicado: (2023)

Susceptibility profile and β-lactamase content of global Pseudomonas aeruginosa isolates resistant to ceftolozane/tazobactam and/or imipenem/relebactam—SMART 2016–21
por: Karlowsky, James A, et al.
Publicado: (2023)

1583. In Vitro Activity of Imipenem/Relebactam against Klebsiella pneumoniae and Pseudomonas aeruginosa from Patients in ICUs in the Asia/Pacific region – SMART 2015-2018
por: Lob, Sibylle, et al.
Publicado: (2020)

Activity of imipenem/relebactam against Enterobacterales and Pseudomonas aeruginosa in Spain. SMART 2016-2020
por: García-Fernández, Sergio, et al.
Publicado: (2023)

597. Cross-resistance of Ceftolozane-Tazobactam and Imipenem-Relebactam Against Clinical P. aeruginosa Isolates: SMART United States 2016–2018
por: Lob, Sibylle, et al.
Publicado: (2019)

1274. Activity of Ceftolozane/Tazobactam, Imipenem/Relebactam, and Comparators Against Pseudomonas aeruginosa Isolates from Patients with Bloodstream and Other Infection Types—SMART United States/Canada 2018-2019
por: Lob, Sibylle, et al.
Publicado: (2021)

Comparison of In Vitro Activity of Ceftazidime-Avibactam and Imipenem-Relebactam against Clinical Isolates of Pseudomonas aeruginosa
por: Wang, Leilei, et al.
Publicado: (2023)

1588. Activity of Imipenem/Relebactam Against Clinical Isolates of P. aeruginosa and K. pneumoniae Collected in Asia/Pacific Countries – SMART 2016-2018
por: Lob, Sibylle, et al.
Publicado: (2020)

1355. Global Activity of Imipenem–Relebactam and Comparators Against Clinical Gram-Negative Pathogens – SMART 2017
por: Lob, Sibylle, et al.
Publicado: (2018)

Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in central and northern Europe (Belgium, Norway, Sweden, Switzerland)—SMART 2017–21
por: Karlowsky, James A, et al.
Publicado: (2023)

1080. Relebactam Increases Imipenem Activity Against Imipenem-Nonsusceptible and -Susceptible Pseudomonas aeruginosa and Enterobacterales: Assessment of Isolates from RESTORE-IMI 2
por: Hilbert, David W, et al.
Publicado: (2021)

Ceftolozane/Tazobactam and Imipenem/Relebactam Cross-Susceptibility Among Clinical Isolates of Pseudomonas aeruginosa From Patients With Respiratory Tract Infections in ICU and Non-ICU Wards—SMART United States 2017–2019
por: Lob, Sibylle H, et al.
Publicado: (2021)

Relebactam restores susceptibility of resistant Pseudomonas aeruginosa and Enterobacterales and enhances imipenem activity against chromosomal AmpC-producing species: analysis of global SMART 2018–2020
por: Hilbert, David W., et al.
Publicado: (2023)

1584. In Vitro Activity of Imipenem/Relebactam against Gram-Negative Pathogens from Patients with Bloodstream Infections in the United States and Canada – SMART 2018
por: Lob, Sibylle, et al.
Publicado: (2020)

1309. Imipenem/Cilastatin/Relebactam (I/R) Alone and in Combination against Pseudomonas aeruginosa (PSA) in the In Vitro Pharmacodynamic Model
por: Chen, Iris H, et al.
Publicado: (2020)

1609. Epidemiology and Susceptibility to Imipenem/Relebactam of Gram-Negative Pathogens from Patients with Lower Respiratory Tract Infections – SMART United States 2017-2018
por: Lob, Sibylle, et al.
Publicado: (2020)

In vitro activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa collected from patients with lower respiratory tract infections in Western Europe: SMART 2018–20
por: Karlowsky, James A, et al.
Publicado: (2023)

1450. Frequency of Carbapenem-resistant Pseudomonas aeruginosa Among Respiratory Pathogens Impacts First-Line Beta-Lactam Susceptibility: Potential Role for Ceftolozane/Tazobactam (C/T) and/or Imipenem/Relebactam (I/R)
por: Klinker, Kenneth, et al.
Publicado: (2020)

2154. Cross-resistance of Ceftolozane-Tazobactam and Imipenem-Relebactam Against Clinical P. aeruginosa Isolates from Bloodstream and Respiratory Tract Infections– SMART United States 2019-2021
por: Lob, Sibylle, et al.
Publicado: (2023)

1718. In Vitro Activity of Imipenem/Relebactam against Class C β-lactamase-Positive Enterobacterales in the Asia/Pacific Region: SMART 2018-2020
por: Lob, Sibylle, et al.
Publicado: (2022)

1280. In-Vitro Activity of Cefiderocol, Imipenem/Relebactam, & Ceftazidime/Avibactam in Ceftolozane/Tazobactam Resistant Strains of Multidrug Resistant Pseudomonas aeruginosa
por: Navas, Daniel, et al.
Publicado: (2020)

Activity of imipenem/relebactam on Klebsiella pneumoniae with different mechanisms of imipenem non-susceptibility
por: Mashaly, Mervat El-Sayed, et al.
Publicado: (2021)

2152. Activity of Imipenem/Relebactam Against Carbapenem-Resistant Non-Morganellaceae Enterobacterales (NME) in the United States – SMART 2019-2021
por: Lob, Sibylle, et al.
Publicado: (2023)

2153. Addition of Relebactam Increases Susceptibility to Imipenem Alone against Class C β-lactamase-Positive Enterobacterales: Asia/Pacific SMART 2019-2021
por: Lob, Sibylle, et al.
Publicado: (2023)

New evidence in severe pneumonia: imipenem/ cilastatin/relebactam
por: Girón, Rosa Mª, et al.
Publicado: (2022)

Effect of Amoxicillin in combination with Imipenem-Relebactam against Mycobacterium abscessus
por: Lopeman, Rose C., et al.
Publicado: (2020)

1671. Activity of Imipenem/Relebactam and Comparators Against Gram-Negative MDR and DTR Pathogens from Patients with Respiratory and Bloodstream Infections – SMART United States 2018-2020
por: Lob, Sibylle, et al.
Publicado: (2022)

Susceptibility to Imipenem/Relebactam of Pseudomonas aeruginosa and Acinetobacter baumannii Isolates from Chinese Intra-Abdominal, Respiratory and Urinary Tract Infections: SMART 2015 to 2018
por: Zhang, Hui, et al.
Publicado: (2021)

Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections
por: Heo, Young-A.
Publicado: (2021)

A Clinical Review and Critical Evaluation of Imipenem-Relebactam: Evidence to Date
por: Campanella, Toni A, et al.
Publicado: (2020)

In Vitro Antibacterial Activity of Imipenem/Relebactam against Clinical Isolates in Japan
por: Kurihara, Dai, et al.
Publicado: (2022)

Mechanisms of Heteroresistance and Resistance to Imipenem in Pseudomonas aeruginosa
por: Xu, Ye, et al.
Publicado: (2020)

2155. Low prevalence of OXA-48-like carbapenemases and susceptibility to imipenem/relebactam among carbapenem-resistant non-Morganellaceae Enterobacterales isolates from Latin America – SMART 2018-2021
por: Lob, Sibylle, et al.
Publicado: (2023)

Role of Relebactam in the Antibiotic Resistance Acquisition in Pseudomonas aeruginosa: In Vitro Study
por: Ventero, Maria Paz, et al.
Publicado: (2023)

Author Correction: Effect of Amoxicillin in combination with Imipenem-Relebactam against Mycobacterium abscessus
por: Lopeman, Rose C., et al.
Publicado: (2020)

Population Pharmacokinetic Analysis for Imipenem–Relebactam in Healthy Volunteers and Patients With Bacterial Infections
por: Bhagunde, Pratik, et al.
Publicado: (2019)

Imipenem/Relebactam Ex Vivo Clearance during Continuous Renal Replacement Therapy
por: Jang, Soo Min, et al.
Publicado: (2021)

Imipenem Resistant Pseudomonas aeruginosa: The fall of the final quarterback
por: Ameen, Nadya, et al.
Publicado: (2015)

Simultaneous administration of imipenem/cilastatin/relebactam with selected intravenous antimicrobials, a stewardship approach
por: Ghazi, Islam M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_18kptjnqn1giiil7giq78km26v